Concepedia

Long-term safety experience of ustekinumab in patients with moderate-to-severe psoriasis (Part I of II): Results from analyses of general safety parameters from pooled Phase 2 and 3 clinical trials

Mark Lebwohl, Craig L. Leonardi, C.E.M. Griffiths, Jörg C. Prinz, Philippe Szapary, Newman Yeilding, Cynthia Guzzo, Shu Li, Ming-Chun Hsu, Bruce Strober

Journal of the American Academy of Dermatology · 2011 · 107 citations · 27 references

DOI

Concepts

References

27

Severe Psoriasis – Oral Therapy with a New Retinoid

T Fredriksson, U. Pettersson · Dermatologica · 2009 · 2.7K citations

, , +11

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

Craig L. Leonardi, Alexa B. Kimball, Kim Papp et al. · The Lancet · 2008 · 1.9K citations

, , +15

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

Kim Papp, Richard G. Langley, Mark Lebwohl et al. · The Lancet · 2008 · 1.4K citations

, , +15

Etanercept as Monotherapy in Patients with Psoriasis

Craig L. Leonardi, JEROLD L. POWERS, Robert Matheson et al. · New England Journal of Medicine · 2003 · 1.2K citations · Full text

, , +16

Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial

Kristian Reich, Frank O. Nestlé, Kim Papp et al. · The Lancet · 2005 · 1K citations

, , +12